Vimarsana
Biggest News Aggregation in the World

Page 27 - Priya Singhal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Priya Singhal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Priya Singhal Today - Breaking & Trending Today

It's Finally Over for Aduhelm, the Sketchy Alzheimer's Drug Everyone Hated - Vimarsana News

It's Finally Over for Aduhelm, the Sketchy Alzheimer's Drug Everyone Hated

The FDA approved Biogen's $56,000 anti-amyloid drug in 2021, against the advice of outside experts.

Biogen to Realign Resources for Alzheimer's Disease Franchise - Vimarsana News

Biogen to Realign Resources for Alzheimer's Disease Franchise

Company to reprioritize resources allocated to ADUHELM® (aducanumab-avwa) to advance LEQEMBI® (lecanemab-irmb) and to develop new treatment modali...

Biogen Inc. (NASDAQ:BIIB) Shares Sold by Arizona State Retirement System - Vimarsana News

Biogen Inc. (NASDAQ:BIIB) Shares Sold by Arizona State Retirement System

Arizona State Retirement System cut its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 0.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,970 shares of the biotechnology company’s stock after selling 331 shares during the quarter. Arizona State Retirement […]

Source: wkrb13.com
Wealthspire Advisors LLC Invests $609,000 in Biogen Inc. (NASDAQ:BIIB) - Vimarsana News

Wealthspire Advisors LLC Invests $609,000 in Biogen Inc. (NASDAQ:BIIB)

Wealthspire Advisors LLC acquired a new position in Biogen Inc. (NASDAQ:BIIB – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 2,369 shares of the biotechnology company’s stock, valued at approximately $609,000. Other large investors have also recently modified their […]

Source: wkrb13.com
Biogen (NASDAQ:BIIB) Rating Reiterated by Oppenheimer - Vimarsana News

Biogen (NASDAQ:BIIB) Rating Reiterated by Oppenheimer

Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “outperform” rating restated by stock analysts at Oppenheimer in a note issued to investors on Tuesday, Benzinga reports. They currently have a $295.00 target price on the biotechnology company’s stock. Oppenheimer’s price objective points to a potential upside of 19.25% from the stock’s previous close. BIIB […]